Aethlon Medical Beheer

Beheer criteriumcontroles 4/4

De CEO Aethlon Medical is Jim Frakes, benoemd in Jan2008, heeft een ambtstermijn van 16.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 416.45K, bestaande uit 100% salaris en 0% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.017% van de aandelen van het bedrijf, ter waarde $ 937.79. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 7 jaar.

Belangrijke informatie

Jim Frakes

Algemeen directeur

US$416.4k

Totale compensatie

Percentage CEO-salaris	100.0%
Dienstverband CEO	16.8yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	7yrs

Recente managementupdates

Recent updates

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Aug 02

FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID

Jul 11

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Mar 18

We're Interested To See How Aethlon Medical (NASDAQ:AEMD) Uses Its Cash Hoard To Grow

Nov 09

Aethlon Medical (AEMD) rockets 63% as FDA amends Hemopurifier IDE for COVID-10 treatment

Dec 16

Aethlon names Charles J. Fisher, Jr., M.D. as CEO

Nov 03

Analyse CEO-vergoeding

Hoe is Jim Frakes's beloning veranderd ten opzichte van Aethlon Medical's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$11m
Jun 30 2024	n/a	n/a	-US$11m
Mar 31 2024	US$416k	US$416k	-US$12m
Dec 31 2023	n/a	n/a	-US$12m
Sep 30 2023	n/a	n/a	-US$12m
Jun 30 2023	n/a	n/a	-US$12m
Mar 31 2023	n/a	n/a	-US$12m
Dec 31 2022	n/a	n/a	-US$13m
Sep 30 2022	n/a	n/a	-US$13m
Jun 30 2022	n/a	n/a	-US$11m
Mar 31 2022	n/a	n/a	-US$10m
Dec 31 2021	n/a	n/a	-US$9m
Sep 30 2021	n/a	n/a	-US$9m
Jun 30 2021	n/a	n/a	-US$9m
Mar 31 2021	US$582k	US$275k	-US$8m
Dec 31 2020	n/a	n/a	-US$7m
Sep 30 2020	n/a	n/a	-US$6m
Jun 30 2020	n/a	n/a	-US$6m
Mar 31 2020	US$355k	US$264k	-US$6m
Dec 31 2019	n/a	n/a	-US$6m
Sep 30 2019	n/a	n/a	-US$7m
Jun 30 2019	n/a	n/a	-US$7m
Mar 31 2019	US$286k	US$256k	-US$6m
Dec 31 2018	n/a	n/a	-US$6m
Sep 30 2018	n/a	n/a	-US$5m
Jun 30 2018	n/a	n/a	-US$5m
Mar 31 2018	US$235k	US$235k	-US$6m

Compensatie versus markt: De totale vergoeding ($USD 416.45K ) Jim } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van Jim is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jim Frakes (67 yo)

16.8yrs

Tenure

US$416,449

Compensatie

Mr. James B. Frakes, also known as Jim, M.B.A. has been the Chief Financial Officer at Aethlon Medical, Inc. since January 2008 and served as its Interim Chief Executive Officer since November 07, 2023 unt...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
James Frakes	CEO, CFO	16.8yrs	US$416.45k	0.017% $ 937.8
Guy Cipriani	Senior VP & COO	less than a year	US$378.06k	0.013% $ 708.9
Steven LaRosa	Chief Medical Officer	3.8yrs	US$430.00k	0% $ 0

3.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van AEMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
James Frakes	CEO, CFO	less than a year	US$416.45k	0.017% $ 937.8
Edward Broenniman	Independent Chairman of the Board	25.7yrs	US$147.50k	0.18% $ 10.2k
Nathan Levin	Member of Extracorporeal Therapy Advisory Board	no data	geen gegevens	geen gegevens
Gregory T. Kovacs	Member of Extracorporeal Therapy Advisory Board	no data	geen gegevens	geen gegevens
Claudio Ronco	Member of Extracorporeal Therapy Advisory Board	no data	geen gegevens	geen gegevens
Larry Cowgill	Member of Sepsis & Inflammation Advisory Board	no data	geen gegevens	geen gegevens
John Kellum	Member of Extracorporeal Therapy Advisory Board	no data	geen gegevens	geen gegevens
Chetan Shah	Independent Director	11.4yrs	US$113.75k	0.15% $ 8.5k
David Ward	Member of Extracorporeal Therapy Advisory Board	no data	geen gegevens	geen gegevens
Irshad Chaudry	Member of Sepsis & Inflammation Advisory Board	no data	geen gegevens	geen gegevens
Geert Schmid-Schönbein	Member of Sepsis & Inflammation Advisory Board	no data	geen gegevens	geen gegevens
Angela Rossetti	Independent Director	2.6yrs	US$113.00k	0.18% $ 9.9k

7.0yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van AEMD wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

Aethlon Medical Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Insufficient new directors

Recent updates

Price target decreased by 45% to US$3.85

New major risk - Revenue and earnings growth

Aethlon Medical Announces Enrollment of the First Patient in (FPI) Its Hemopurifier Cancer Trial in Australia

Aethlon Medical, Inc. to Report Q2, 2025 Results on Nov 13, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier Cancer Trial in India

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical Announces Activation of Royal Adelaide Hospital to Begin Patient Screening and Enrollment in Hemopurifier Cancer Trial

Aethlon Medical, Inc. Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Extracellular Vesicles and MicroRNAs from Renal Perfusates Following Controlled Oxygenated Rewarming of Donor Kidneys

Aethlon Medical, Inc., Annual General Meeting, Sep 27, 2024

Aethlon Medical, Inc. Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial

Aethlon Medical, Inc. to Report Q1, 2025 Results on Aug 14, 2024

Aethlon Medical, Inc. to Report Fiscal Year 2024 Results on Jun 27, 2024

Aethlon Medical, Inc. Receives Ethics Committee Approval for Hemopurifier® Cancer Trial

Aethlon Medical, Inc. Prepares for Potentially Transformative Phase 1 Cancer Treatment Studies

New major risk - Shareholder dilution

Aethlon Medical, Inc. has completed a Follow-on Equity Offering in the amount of $4.69235 million.

New major risk - Share price stability

Aethlon Medical, Inc. Reports Positive Results from an In Vitro Binding Study of Its Hemopurifier in Removing Extracellular Vesicles from Cancer Patient Plasma

Aethlon Medical, Inc. has filed a Follow-on Equity Offering in the amount of $16.32 million.

Price target increased by 27% to US$40.10

Aethlon Medical, Inc. to Report Q3, 2024 Results on Feb 14, 2024

New major risk - Financial position

Aethlon Medical, Inc. Announces Appointment Ofguy Ciprian as Chief Operating Officer

Aethlon Medical, Inc. to Report Q2, 2024 Results on Nov 14, 2023

Price target decreased by 21% to US$31.55

Price target decreased by 90% to US$4.01

Aethlon Medical, Inc. Receives Clearance from Drug Controller General of India for Potential Phase 1 Trial of its Hemopurifier(R) in Oncology

Aethlon Medical, Inc. to Report Q1, 2024 Results on Aug 10, 2023

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2023

Price target decreased by 12% to US$6.50

Aethlon Medical, Inc. Appoints Nicolas Gikakis as Member of the Board and Member of the Nominating Committee

New major risk - Shareholder dilution

Full year 2023 earnings released: US$0.59 loss per share (vs US$0.71 loss in FY 2022)

Aethlon Medical, Inc. to Report Q4, 2023 Results on Jun 28, 2023

New major risk - Share price stability

No longer forecast to breakeven

Third quarter 2023 earnings released: US$0.12 loss per share (vs US$0.16 loss in 3Q 2022)

Aethlon Medical, Inc. to Report Q3, 2023 Results on Feb 13, 2023

Forecast to breakeven in 2023

No longer forecast to breakeven

First half 2023 earnings released: US$0.37 loss per share (vs US$0.29 loss in 1H 2022)

Aethlon Medical, Inc. to Report Q2, 2023 Results on Nov 14, 2022

Aethlon Medical Receives Non-Compliance Notice of Delisting from Nasdaq

Aethlon Medical, Inc. Announces Early Feasibility Study of the Hemopurifier

Forecast to breakeven in 2023

First quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Aethlon Medical, Inc. to Report Q1, 2023 Results on Aug 09, 2022

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Aethlon Medical, Inc., Annual General Meeting, Sep 15, 2022

Aethlon Medical, Inc. Announces U.S. FDA Approval of Hemopurifier COVID-19 Study Protocol Amendment

FDA approves protocol change in Aethlon's trial of its purifier to treat severe COVID

Consensus revenue estimates fall by 100%

Aethlon Medical, Inc. to Report Fiscal Year 2022 Results on Jun 28, 2022

Price target decreased to US$7.00

Consensus revenue estimates increase by 178%

Insufficient new directors

Consensus revenue estimates increase by 178%

Aethlon Medical, Inc. Announces Executive Changes

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate

Consensus revenue estimates fall by 68%

Aethlon Medical, Inc. to Report Q3, 2022 Results on Feb 14, 2022

Insufficient new directors

We're Interested To See How Aethlon Medical (NASDAQ:AEMD) Uses Its Cash Hoard To Grow

Consensus revenue estimates fall to US$1.24m

Full year 2021 earnings released: US$0.65 loss per share (vs US$1.87 loss in FY 2020)

Aethlon Medical climbs on Reddit interest

Aethlon Medical, Inc. Publishes Case Studies of Two Critically ill Covid-19 Patients Treated with the Hemopurifier®

Forecast to breakeven in 2023

We're Keeping An Eye On Aethlon Medical's (NASDAQ:AEMD) Cash Burn Rate